Arthur Taveras - Mar 1, 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role: Chief Scientific Officer
Signature: Derek M. Meisner, attorney-in-fact
Stock symbol: XFOR
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/1/2022, 03:09 PM
Previous filing: Feb 14, 2022
Next filing: Nov 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XFOR	Common Stock	Award	$0	+97K	+1364.85%	$0.00	104K	Mar 1, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
F2	Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units.

Content

Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units.